logo

IMCR

Immunocore·NASDAQ
--
--(--)
--
--(--)
3.17 / 10
Netural

IMCR's fundamental picture is rated poor (3.2/10). Key strengths include Profit-MV, Cash-MV, and an exceptional Gross profit margin (%) of 99.19, which earns a top score of 3. However, critical weaknesses such as Net profit / Total profit (%) at 164.97 (score 0) and negative Revenue-MV (-0.80) significantly drag performance. Asset-MV (-0.50) also falls short, while Fixed assets turnover ratio (30.27) is a minor bright spot. The composite score of 3.17 reflects an unfavorable fundamental setup that warrants selective consideration.

Fundamental(3.17)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.80
Score1/3
Weight10.39%
1M Return5.20%
Inventory turnover ratio
Value0.43
Score2/3
Weight-3.94%
1M Return-2.63%
Gross profit margin (%)
Value99.19
Score3/3
Weight20.88%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight15.55%
1M Return7.79%
PB-ROE
Value0.58
Score0/3
Weight7.10%
1M Return3.56%
Current assets turnover ratio
Value0.30
Score1/3
Weight-0.78%
1M Return-0.48%
Fixed assets turnover ratio
Value30.27
Score2/3
Weight0.20%
1M Return0.12%
Asset-MV
Value-0.50
Score2/3
Weight35.49%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight15.58%
1M Return7.73%
Net profit / Total profit (%)
Value164.97
Score0/3
Weight-0.46%
1M Return-0.30%
Is IMCR undervalued or overvalued?
  • IMCR scores 3.17/10 on fundamentals and holds a Fair valuation at present. Backed by its -1.44% ROE, -7.70% net margin, -55.29 P/E ratio, 4.07 P/B ratio, and 38.95% earnings growth, these metrics solidify its Netural investment rating.